A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants

Summary

This study plans to enroll 45 (Groups A, B, and C) to 75 healthy participants (including the sample size of other potential dose groups). The participants will be divided into three dose groups: 37.5 mg, 75 mg, and 150 mg. After taking the corresponding investigational product, participants are required to complete test procedures including QTc interval measurement , blood sampling, and vital sign monitoring. The entire test process lasts for 3 days. On the third day, after participants complete laboratory tests and are assessed by physicians as meeting the discharge criteria, they can be discharged.

Timeline

Start

2025-07-06

Primary completion

2025-12-01

Completion

2026-05

Drugs

Indications